Polaris doses first pediatric patient with ADI-PEG 20
Polaris Group is announcing that they have dosed the first patient in the company's Phase I safety and efficacy clinical trial in the evaluation of their oncology candidate, pegylated arginine deiminase (ADI-PEG 20).
ADI-PEG 20 is being investigated as a treatment against pediatric cases of lymphoma, leukemia and some sarcomas.
The trial is being carried out at MD Anderson Cancer Center in Texas.
Said John Bomalaski, M.D., Polaris' Executive Vice President of Medical Affairs, "We are delighted to begin this first study of ADI-PEG 20 in pediatric patients. We believe ADI-PEG 20 is a promising cancer therapeutic for these cancers, and we plan to initiate Phase 2 studies in adults with these cancers."
ADI-PEG 20 is currently being investigated as a monotherapy in a Phase III trial against hepatocellular carcinoma; Phase II trials against small cell lung carcinoma and mesothelioma; and a Phase I trial in combination with docetaxel against prostate cancer
Source: MarketWatch
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
